Physician Wealth Advisors’s Alkermes ALKS Stock Holding History

Physician Wealth Advisors’s Portfolio ALKS Stock Details ALKS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$996	Hold	19	–	–	﹤0.01%	1840
2026 Q1	$672	Buy	+19	New	+$589	﹤0.01%	1817
2025 Q3	–	Sell	-21	Closed	-$601	–	1905
2025 Q2	$601	Buy	+21	New	+$625	﹤0.01%	1662

Other funds holding ALKS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Physician Wealth Advisors's ALKS Position: Q2 2026 in Review

Physician Wealth Advisors held its Alkermes (ALKS) position steady in Q2 2026 at 19 shares worth $996. The position accounts for ﹤0.01% of the portfolio, ranked #1840.

Physician Wealth Advisors first reported a position in ALKS in Q2 2025 and has held it in 3 quarters since. 425 funds tracked by Wall St. Rank hold ALKS as of Q2 2026.

Physician Wealth Advisors held 19 shares of Alkermes worth $996 as of Q2 2026.
Physician Wealth Advisors left its Alkermes share count unchanged in Q2 2026.
Alkermes made up ﹤0.01% of Physician Wealth Advisors's portfolio in Q2 2026, its #1840 holding.
Physician Wealth Advisors first reported a position in Alkermes in Q2 2025 and has held it in 3 quarters since.
425 funds tracked by Wall St. Rank held Alkermes as of Q2 2026.

Based on Physician Wealth Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.